23andMe, FDA and DNA health profiling

Подробнее о видео

Are companies that provide direct-to-consumer information on their personal genome -- including genetic susceptibility to disease -- creating new health risks that need to be regulated?

On November 22 2013, the US Food and Drug Administration requested that the personalized DNA analysis company 23andMe "immediately discontinue marketing the PGS [Personal Genome Service] until such time as it receives FDA marketing authorization for the device".

This week, Risk Bites looks at some of the questions raised by FDA's response to 23andMe's DNA Spit Test

The Risk Bites Team:
Producer: Andrew Maynard
Research Director: David Faulkner

Risk Bites is supported by:
University of Michigan School of Public Health.
University of Michigan Risk Science Center.

RESOURCES
23andMe:
Letter from FDA to 23andMe:
David Dobbs: FDA Muzzles 23andMe After Talks Break Down
TechCrunch:
Wall Street Journal:
CNN:

Risk Bites is your guide to making sense of risk. We cover everything from understanding and balancing the risks and benefits of everyday products, to health science more broadly, to the potential impacts of emerging technologies, to making sense of risk perception. If you enjoy our videos, please subscribe, and spread the word!